Bedrail entrapment: Is your facility safe?

Braun, Julie A.; Capezuti, Elizabeth A.
November 2004
Nursing Homes: Long Term Care Management;Nov2004, Vol. 53 Issue 11, p56
Trade Publication
Presents risk management strategies which aimed to reduce bedrail entrapments in various care settings such as nursing homes and hospitals. Members of the Hospital Bed Safety Workgroup; Contents of the "Draft Guidance for Industry and FDA Staff: Hospital Bed System Dimensional Guidance to Reduce Entrapment," released by the U.S. Food and Drug Administration (FDA); Products excluded from the dimensional criteria; Important details recommended by the FDA to improve the quality of entrapment event reports.


Related Articles

  • Risky-drugs list in the spotlight. Rhea, Shawn // Modern Healthcare;8/9/2010, Vol. 40 Issue 32, p14 

    The article reports that healthcare professionals, patient groups and drug manufacturers are concerned about the list of drug-safety requirements issued under the U.S. Food and Drug Administration's Risk Evaluation and Mitigation Strategies (REMS). They agree that the program is needed to allow...

  • LEGAL LANDSCAPE. Sidetracked by side rails. HOROWITZ, ALAN C. // Long-Term Living: For the Continuing Care Professional;Sep/Oct2015, Vol. 64 Issue 5, p12 

    The article discusses that the use of side rails for nursing homes should be the exception rather than the norm subject to a risk-benefit analysis for each resident. Topics covered are the side rail entrapment-related death at Laurelwood Care Center, the recommendation to obtain the informed...

  • EarlySense Receives FDA Clearance and CE Approval for the Wireless Network Option of its Contact-Free Patient Monitoring Solution.  // Biomedical Market Newsletter;6/19/2011, p954 

    The article reports that EarlySense had received clearance from U.S. Food and Drug Administration (FDA) and CE approval for its new wireless (WiFi) communications component for patient monitoring solutions for hospitals and nursing homes. It states that the patient monitoring system...

  • Keeping Approvals on TRACK. Gliklich, Richard // Applied Clinical Trials;Aug2005, Vol. 14 Issue 8, p28 

    Reports on the reaction of the public involving the approval of the Cox-2 inhibitors and antidepressants by the U.S. Food and Drug Administration. Technologies and methodologies applied in Phase IV safety studies and registries; Change to paradigm to proactive and systematic postapproval...

  • US dermatologists seek to delay start of iPLEDGE programme.  // Reactions Weekly;2/18/2006, Issue 1089, p4 

    Reports on the call of the American Academy of Dermatology Association for the delay in the implementation of the iPLEDGE program, a mandatory isotretinoin risk management initiative approved by the U.S. Food and Drug Administration. Safety concerns raised by the association; Impact of the...

  • FDA considers making changes to RiskMAPs. Foxhall, Kathryn // Drug Topics;7/23/2007, Vol. 151 Issue 14, p55 

    The article reports that the U.S. Food Drug and Administration has approved making changes to Risk Minimization Action Plans (RiskMAPs). RiskMAPs allow the medication to be administered only to patients enrolled in the risk management plan and prescribed, distributed and infused only by...

  • Praecis in discussions with FDA relating to Plenaxis NDA.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p19 

    Reports that the Plenaxis prostate cancer product of Praecis Pharmaceuticals is under review by the United States Food and Drug Administration. Focus on patients with advanced prostate cancer; Risk management program of Praecis.

  • Second Look Advocacy.  // AAOS Now;Oct2014, Vol. 8 Issue 10, p22 

    The article offers news briefs related to advocacy in the U.S. as of October 2014. The Joint Commission has released a Sentinel Event Alert on risk management during the transition to tubing connector standards. The Food and Drug Administration has recalled sterile convenience surgical packs...

  • CMS Seeks to Reduce Antipsychotic Use in Nursing Home Residents With Dementia. Mitka, Mike // JAMA: Journal of the American Medical Association;7/11/2012, Vol. 308 Issue 2, p119 

    The article presents information on the decision of Centers for Medicare & Medicaid Services (CMS) related to the improper antipsychotic medications for dementia in the patients of various nursing homes in the U.S. It informs that in the year 2005 the U.S. Food and Drug Administration (FDA) has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics